Streptokinase (SK) is being increasingly used in the treatment of acute myocardial infarction and ischemic stroke. The feeding control method using substrate balance equations is vital to maintain the preferred specific growth rate for the high-level expression of recombinant proteins. In this study, initial experiments on chemical and temperature inducible expression systems were carried out t...

Background. Streptokinase is a routinely used thrombolytic agent that is immunogenic and relatively inefficient toward platelet-rich thrombus, whereas staphylokinase is a poorly studied fibrinolytic agent. Here, the comparative immunogenicity and thrombolytic properties toward arterial platelet-rich thrombus and venous whole blood clots of streptokinase and recombinant staphylokinase were studi...

BACKGROUND Streptokinase is a potent activator of plasminogen to plasmin, the enzyme that can solubilize the fibrin network in blood clots. Streptokinase is currently used in clinical medicine as a thrombolytic agent. It is naturally secreted by β-hemolytic streptococci. METHODS To reach an efficient method of purification, an immunoaffinity chromatography method was developed that could puri...

BACKGROUND Streptokinase is the most widely used thrombolytic agent and can now be made using recombinant DNA technology. The present trial was initiated to assess an indigenous recombinant streptokinase (Shankinase, r-SK). AIM To compare the efficacy and safety of indigenous recombinant streptokinase (Shankinase, r-SK) and natural streptokinase (Streptase, n-SK). SETTINGS AND DESIGN Double...

Failure of hemostasis and the formation blood clots in arteries are main reasons that provoke onset cardiovascular diseases (CVDs) such as myocardial infarction ischemic stroke. Cardiovascular have become primary cause deaths disabilities across globe. Therefore, this problem needs to be addressed with urgency. The disintegration requires fibrinolytic agents, which involved thrombolysis. Strept...

I would like to comment about Heberkinasa (recombinant streptokinase): one of the preparations included in the article written by Dr Hermentin et al. 1 The quality control system of the Center of Genetic Engineering and Biotechnology has been successfully evaluated by the World Health Organization and another International Regulatory Organizations. The biological activity of the Heberkinasa bat...

BACKGROUND Worldwide, streptokinase remains the most used thrombolytic agent for the treatment of myocardial infarction. Recombinant streptokinase, from E. coli, is increasingly used in developing countries as a biosimilar of native streptokinase; however, potency assignments relative to the WHO International Standard (IS) are highly variable with potentially dangerous consequences. A proportio...

Fibrinolytic enzymes, particularly streptokinase, are now widely used to treat empyema thoracis. Recent in vitro evidence suggests that streptokinase has no effect on pus viscosity but that deoxyribonuclease (DNase) reduces the viscosity of pus. We report the first use of human recombinant DNase given intrapleurally to treat an empyema which had not resolved after standard treatment with strept...

Determination of streptokinase activity is usually accomplished through two assay methods: a) Clot lysis, b) Chromogenic substrate assay. In this study the biological activity of two streptokinase products, namely Streptase®, which is a native product and Heberkinasa®, which is a recombinant product, was determined against the third international reference standard using the two forementioned a...

Determination of streptokinase activity is usually accomplished through two assay methods: a) Clot lysis, b) Chromogenic substrate assay. In this study the biological activity of two streptokinase products, namely Streptase®, which is a native product and Heberkinasa®, which is a recombinant product, was determined against the third international reference standard using the two forementioned a...